Stocks · News reference
Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price target from $24 to $33.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 49.11 percent increase over losses of $(1.12) per share from the
Read original at benzingaSCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $(0.64) by 198.44 percent. This is a 156.25 percent increase over losses of $(1.12) per share from the
Read original at benzingahttps://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2636#
Read original at benzinga